Die Patienten in Gruppe A erhielten einmal wöchentlich 162 mg RoACTEMRA subkutan; die Patienten in Gruppe B erhielten alle 4 Wochen 8 mg/kg RoACTEMRA intravenös. ###>Patients in group A received RoACTEMRA 162 mg SC weekly and those in group B received RoACTEMRA 8 mg/kg IV every 4 weeks.